UNSPSC 51372703: Meptazinol hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C15H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T62FQ4ZCPA, chemically known as phenol, 3-(3-ethylhexahydro-1-methyl-1h-azepin-3-yl)- but more generally known as meptazinol hydrochloride, which bears US NIH Compound Identifier 41049. European Medicines Agency schedules Meptazinol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03161MIG.

Most nations, for tariff and trade purposes, schedule meptazinol hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, MEPTAZINOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Meptazinol hydrochloride bears US NLM identifiers UMLS ID C0043281 and NCI Concept Code C87361. SMILES: CCC1(CCCCN(C1)C)C2CCCC(C2)O.CL.

UNSPSC 51372703 Meptazinol hydrochloride, a Commodity-tier code, covers pharmaceutical products that state and local governments procure through health agencies and public purchasing cooperatives, though recent activity shows minimal direct solicitation for this specific opioid formulation. Instead, state and local buyers are acquiring naloxone, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate purchasing cooperatives administering pooled pharmaceutical procurement for state agencies and local government facilities across multiple jurisdictions. Vendors typically must hold current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, maintain relationships with authorized wholesalers, and submit detailed National Drug Code product specifications alongside pricing models—fixed price, net price formats, or WAC-minus structures.

Recent solicitations center in Texas and Minnesota, with multistate cooperative reach. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring award by May 15, 2026 for July 1, 2026 contract effectiveness across participating state and local facilities in Minnesota and Oregon. Texas HHS Commission posted an RFI on April 3, 2026 exploring direct-to-manufacturer prescription programs to gather vendor capabilities for future formal solicitation. Vendors pursuing this code should expect compliance certifications, multi-wholesaler relationships, and pricing transparency requirements typical of government pharmacy procurement.